Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0204

Medical education · Dr. Noor Sato

10 Jul 2026 · Virtual · Dr. Noor Sato, Royal Melbourne Hospital · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0204MI request

Capture insight from this engagement

Location: Royal Melbourne Hospital
Therapeutic area: Neurology
Country: Australia
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Switching between CGRP agents

Scientific content used

Chronic migraine scientific platform

Questions raised

No questions recorded.

Notes

Medical education with primary care physician at Royal Melbourne Hospital. Discussed switching between cgrp agents.

Insights captured (1)

Capture insight

INS-0008Medium
Switching between CGRP agents
Switching between CGRP agents: request for data reported by primary care physician (AU).
Outcome recorded

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 5
Depth of exchange: 5
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0204

Audit history (0)

All create, update and approval events for this record

No audit events in sample data